The purpose of this study is to understand current real-world treatment patterns and clinical outcomes, reasons for switching treatment, and participant characteristics using each systemic psoriasis treatment in Japan.
Study Type
OBSERVATIONAL
Enrollment
114
Local Institution
Minato-ku, Tokyo, Japan
Distribution of participant background at first visit: Age
Time frame: At Baseline
Distribution of participant background at first visit: Sex
Time frame: At Baseline
Distribution of participant background at first visit: Duration with psoriasis
Time frame: At Baseline
Distribution of participant background at first visit: Comorbidities
Time frame: At Baseline
Distribution of participant background at first visit: Current status of phototherapy
Time frame: At Baseline
Treatment patterns: Drug names treated during study period
Time frame: Up to 4 years
Treatment patterns: Drug categories treated during study period
Time frame: Up to 4 years
Treatment patterns: Number of treatment changes during study period
Time frame: Up to 4 years
Treatment patterns: Treatment duration of each drug during study period
Time frame: Up to 4 years
Treatment patterns: Duration between withdrawal of one drug and start of a new drug during study period
Time frame: Up to 4 years
Treatment patterns: Adverse event (AE) at time of withdrawal of some drug
Time frame: Up to 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Treatment patterns: Psoriasis area severity index (PASI) at time of withdrawal
Time frame: Up to 4 years
Treatment patterns: PASI at time of start of a new drug
Time frame: Up to 4 years
Treatment patterns: PASI improvement from start of one drug to withdrawal of other drug
Time frame: Up to 4 years
Treatment patterns: Reason for treatment change during study period
Time frame: Up to 4 years
Treatment patterns: Status of phototherapy combination with systemic treatment
Time frame: Up to 4 years
Distribution of comorbidities that affect treatment choice and change
Time frame: Up to 4 years
Distribution of AEs that affect treatment choice and change
Time frame: Up to 4 years
Mean number of drug changes until participants achieve PASI 75 during study period
75% reduction in the Psoriasis Area and Severity Index score (PASI 75)
Time frame: Up to 4 years
Mean number of drug changes until participants achieve PASI 90 during study period
90% reduction in the Psoriasis Area and Severity Index score (PASI 90)
Time frame: Up to 4 years
Mean number of drug changes until participants achieve PASI 100 during study period
100% reduction in the Psoriasis Area and Severity Index score (PASI 100)
Time frame: Up to 4 years
Total period until participants achieve PASI 75 during study period
Time frame: Up to 4 years
Total period until participants achieve PASI 90 during study period
Time frame: Up to 4 years
Total period until participants achieve PASI 100 during study period
Time frame: Up to 4 years
Mean period of participants achieve PASI 75 by each systemic treatment
Time frame: Up to 4 years
Mean period of participants achieve PASI 90 by each systemic treatment
Time frame: Up to 4 years
Mean period of participants achieve PASI 100 by each systemic treatment
Time frame: Up to 4 years
Description of relationship between the reasons for treatment change and period of withdrawal
Time frame: Up to 4 years
Efficacy after re-start treatment measured by PASI
Time frame: Up to 4 years